Brainstorm Cell Therapeutics Inc.
BCLI
$1.00
$0.011.01%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.65M | 1.28M | 1.39M | 1.15M | 1.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.61M | 2.05M | 2.24M | 2.05M | 2.57M |
| Operating Income | -3.61M | -2.05M | -2.24M | -2.05M | -2.57M |
| Income Before Tax | -3.86M | -2.13M | -2.43M | -2.11M | -2.90M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.86M | -2.13M | -2.43M | -2.11M | -2.90M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.86M | -2.13M | -2.43M | -2.11M | -2.90M |
| EBIT | -3.61M | -2.05M | -2.24M | -2.05M | -2.57M |
| EBITDA | -3.57M | -2.01M | -2.20M | -2.00M | -2.52M |
| EPS Basic | -0.35 | -0.19 | -0.22 | -0.19 | -0.34 |
| Normalized Basic EPS | -0.22 | -0.12 | -0.14 | -0.12 | -0.21 |
| EPS Diluted | -0.35 | -0.19 | -0.22 | -0.19 | -0.34 |
| Normalized Diluted EPS | -0.22 | -0.12 | -0.14 | -0.12 | -0.21 |
| Average Basic Shares Outstanding | 11.03M | 11.03M | 11.05M | 11.01M | 8.62M |
| Average Diluted Shares Outstanding | 11.03M | 11.03M | 11.05M | 11.01M | 8.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |